Hints and tips:
Related Special Reports
...WPP’s Ogilvy advertising agency is creating a division specialising in online “health influencers” to help pharmaceutical companies tap a trend towards personalised health and combat misinformation....
...Soriot already earns more than bosses of larger European pharmaceutical companies....
...Curaleaf is the world’s largest cannabis company, with a market capitalisation of C$4.6bn, and its shares have risen 40 per cent in the past year....
...The British pharmaceutical company is preparing for a vote on its long-serving leader’s pay at the annual meeting on Thursday, including a rise that would take his package to a maximum of £18.7mn....
...Although payment reporting standards differ between countries, Soriot receives higher pay than totals reported for other European pharmaceutical executives but is paid slightly less than some US peers....
...No concessions of liability have been made,” the company said....
...AstraZeneca has acquired oncology biotech Fusion Pharmaceuticals for $2.4bn to build its expertise and challenge Swiss company Novartis in the developing field of a more targeted form of radiotherapy....
...company’s biggest-selling drugs....
...It is a similar milestone-based structure to many partnerships in the pharmaceutical industry....
Technique highlights concerns shifting global disease burden as populations age
...Over the decades, studies have repeatedly shown these gender disparities persisting: men are more likely to be prescribed painkillers while women have to make do with psycho-pharmaceutical interventions....
...“Adrian van den Hoven, director-general of Medicines for Europe, an industry body representing European pharmaceutical companies, said that ambiguity around the new anti-espionage law had led to concerns...
...Panuwat’s company, Medivation, was bought in 2016 by Pfizer for $14bn. But the stock he purchased at the time was not that of Medivation....
...It needs further deals to replenish its pharmaceuticals pipeline....
...The case is the latest in a series of intellectual property battles that companies are fighting around the world over mRNA technology, which has helped generate billions in revenues for the pharmaceuticals...
...“The company’s main biological asset are NHPs used for pre-clinical trials....
...Emblaveo, marketed in Europe by US pharmaceutical company Pfizer, combines two existing medicines to tackle so-called Gram-negative bacteria that are among the leading drug-resistance threats....
...Many international companies in the consumer goods, pharmaceuticals, retail and manufacturing sectors have continued to do business in Russia, despite a widespread corporate exodus and successive rounds...
...Any rumours that the company is at risk of defaulting are “flatly untrue”, he said....
...Last year, at the height of pricing negotiations, leaders from 16 of the world’s largest generic and biosimilar companies wrote asking for clarity on specific aspects of the deal....
...“The biggest barrier is insurance companies,” said Lawrence Honig, a neurologist at New York’s Columbia University Irving Medical Center....
...The company has warned of zero free cash flow for 2023....
...Avid Bioservices, a small-cap company that helps develop and manufacture drugs for pharmaceutical companies, filed this with the SEC yesterday: On February 29, 2024, Avid Bioservices, Inc....
...Like many European pharmaceutical companies, it makes a large proportion of sales in the US....
...Pharmaceutical companies also have a key role to play in providing affordable access to these essential products. The global industry’s response to date has been inadequate and fragmented....
International Edition